Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Innes AJ"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-9 z 9
    Tytuł:
    FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions.
    Autorzy:
    May PC; Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, UK.; Specialist Integrated Haematological Malignancy Service, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, UK.
    Reid AG; North West Genomic Laboratory Hub, Manchester NHS Foundation Trust, Manchester, UK.
    Robinson ME; Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
    Khorashad JS; Clinical Genomics, The Centre for Molecular Pathology, The Royal Marsden NHS Foundation Trust, London, UK.
    Milojkovic D; Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, UK.; Department of Clinical Haematology, Imperial College Healthcare NHS Trust, London, UK.
    Claudiani S; Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, UK.; Department of Clinical Haematology, Imperial College Healthcare NHS Trust, London, UK.
    Willis F; Department of Haematology, St George's University NHS Foundation Trust, London, UK.
    Apperley JF; Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, UK.; Department of Clinical Haematology, Imperial College Healthcare NHS Trust, London, UK.
    Innes AJ; Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, UK. a.innes@imperial.ac.uk.; Department of Clinical Haematology, Imperial College Healthcare NHS Trust, London, UK. a.innes@imperial.ac.uk.
    Pokaż więcej
    Corporate Authors:
    Genomics England Research Consortium
    Źródło:
    BMC medical genomics [BMC Med Genomics] 2023 Jul 26; Vol. 16 (1), pp. 172. Date of Electronic Publication: 2023 Jul 26.
    Typ publikacji:
    Case Reports; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Fusion Proteins, bcr-abl*/genetics
    Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/diagnosis
    Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics
    Female ; Humans ; Adult ; Retrospective Studies ; In Situ Hybridization, Fluorescence ; Translocation, Genetic ; RNA-Directed DNA Polymerase/genetics
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Long-term persistence of natural anti-SARS-CoV-2 antibodies and mild impact of SARS-CoV-2 infection in CML patients: results from a seroprevalence study.
    Autorzy:
    Claudiani S; Department of Immunology and Inflammation, Faculty of Medicine, Centre for Haematology, Hammersmith Campus, Imperial College London, London, UK.
    Parker EL; Department of Infectious Disease, Faculty of Medicine, St Mary's Campus, Imperial College London, London, UK.
    Milojkovic D; Department of Immunology and Inflammation, Faculty of Medicine, Centre for Haematology, Hammersmith Campus, Imperial College London, London, UK.
    Rosadas C; Department of Infectious Disease, Faculty of Medicine, St Mary's Campus, Imperial College London, London, UK.
    Khan A; Department of Immunology and Inflammation, Faculty of Medicine, Centre for Haematology, Hammersmith Campus, Imperial College London, London, UK.
    Katsanovskaja K; Department of Infectious Disease, Faculty of Medicine, St Mary's Campus, Imperial College London, London, UK.
    Marchesin F; Department of Infectious Disease, Faculty of Medicine, St Mary's Campus, Imperial College London, London, UK.
    Khan M; Department of Infectious Disease, Faculty of Medicine, St Mary's Campus, Imperial College London, London, UK.
    Tedder RS; Department of Infectious Disease, Faculty of Medicine, St Mary's Campus, Imperial College London, London, UK.
    Innes AJ; Department of Immunology and Inflammation, Faculty of Medicine, Centre for Haematology, Hammersmith Campus, Imperial College London, London, UK.
    McClure MO; Department of Infectious Disease, Faculty of Medicine, St Mary's Campus, Imperial College London, London, UK.
    Apperley JF; Department of Immunology and Inflammation, Faculty of Medicine, Centre for Haematology, Hammersmith Campus, Imperial College London, London, UK.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2022 Jun; Vol. 63 (6), pp. 1504-1507. Date of Electronic Publication: 2022 Jan 24.
    Typ publikacji:
    Letter
    MeSH Terms:
    COVID-19*/epidemiology
    Antibodies, Viral ; Humans ; Immunoglobulin G ; SARS-CoV-2 ; Seroepidemiologic Studies
    Opinia redakcyjna
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial.
    Autorzy:
    Vergis N; Imperial College, London and Imperial NHS Trust, London, UK. .
    Phillips R; Imperial Clinical Trials Unit and Imperial College, London, UK.
    Cornelius V; Imperial Clinical Trials Unit and Imperial College, London, UK.
    Katsarou A; Imperial College, London and Imperial NHS Trust, London, UK.
    Youngstein T; Imperial College, London and Imperial NHS Trust, London, UK.
    Cook L; Imperial College, London and Imperial NHS Trust, London, UK.
    Willicombe M; Imperial College, London and Imperial NHS Trust, London, UK.
    Pilay C; Imperial College, London and Imperial NHS Trust, London, UK.
    Shturova T; Imperial College, London and Imperial NHS Trust, London, UK.
    Almonte M; Imperial College, London and Imperial NHS Trust, London, UK.
    Charania A; Imperial College, London and Imperial NHS Trust, London, UK.
    Turner R; Imperial College, London and Imperial NHS Trust, London, UK.
    Kon OM; Imperial College, London and Imperial NHS Trust, London, UK.
    Cooke G; Imperial College, London and Imperial NHS Trust, London, UK.
    Thursz M; Imperial College, London and Imperial NHS Trust, London, UK.
    Cherlin S; Newcastle Clinical Trials Unit and Newcastle University, Newcastle upon Tyne, UK.
    Wason J; Newcastle Clinical Trials Unit and Newcastle University, Newcastle upon Tyne, UK.
    Milojkovic D; Imperial College, London and Imperial NHS Trust, London, UK.
    Innes AJ; Imperial College, London and Imperial NHS Trust, London, UK.
    Cooper N; Imperial College, London and Imperial NHS Trust, London, UK.
    Pokaż więcej
    Źródło:
    Trials [Trials] 2021 Apr 12; Vol. 22 (1), pp. 270. Date of Electronic Publication: 2021 Apr 12.
    Typ publikacji:
    Clinical Trial Protocol; Letter
    MeSH Terms:
    COVID-19 Drug Treatment*
    Oxazines/*therapeutic use
    Pyrazoles/*therapeutic use
    Pyridines/*therapeutic use
    Adult ; Aminopyridines ; Humans ; Morpholines ; Nitriles ; Pandemics ; Pyrimidines ; Randomized Controlled Trials as Topic ; Respiration, Artificial ; Treatment Outcome ; Venous Thromboembolism/prevention & control
    Opinia redakcyjna
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    BKV-specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation.
    Autorzy:
    Pello OM; Centre for Haematology, Imperial College at Hammersmith Hospital, London, UK.
    Innes AJ; Centre for Haematology, Imperial College at Hammersmith Hospital, London, UK.
    Bradshaw A; Centre for Haematology, Imperial College at Hammersmith Hospital, London, UK.
    Finn SA; Centre for Haematology, Imperial College at Hammersmith Hospital, London, UK.
    Uddin S; Centre for Haematology, Imperial College at Hammersmith Hospital, London, UK.
    Bray E; Centre for Haematology, Imperial College at Hammersmith Hospital, London, UK.
    Olavarria E; Centre for Haematology, Imperial College at Hammersmith Hospital, London, UK.
    Apperley JF; Centre for Haematology, Imperial College at Hammersmith Hospital, London, UK.
    Pavlů J; Centre for Haematology, Imperial College at Hammersmith Hospital, London, UK.
    Pokaż więcej
    Źródło:
    European journal of haematology [Eur J Haematol] 2017 Jun; Vol. 98 (6), pp. 632-634. Date of Electronic Publication: 2017 Mar 01.
    Typ publikacji:
    Case Reports
    MeSH Terms:
    Immunotherapy, Adoptive*
    Cystitis/*therapy
    Hematopoietic Stem Cell Transplantation/*adverse effects
    Hemorrhage/*therapy
    Polyomavirus Infections/*therapy
    T-Lymphocytes/*transplantation
    Tumor Virus Infections/*therapy
    Adult ; BK Virus/pathogenicity ; BK Virus/physiology ; Cystitis/etiology ; Cystitis/immunology ; Cystitis/pathology ; Hemorrhage/etiology ; Hemorrhage/immunology ; Hemorrhage/pathology ; Histocompatibility Testing ; Humans ; Leukemia, Myeloid, Acute/immunology ; Leukemia, Myeloid, Acute/pathology ; Leukemia, Myeloid, Acute/therapy ; Male ; Polyomavirus Infections/etiology ; Polyomavirus Infections/immunology ; Polyomavirus Infections/pathology ; Transplantation, Isogeneic ; Treatment Outcome ; Tumor Virus Infections/etiology ; Tumor Virus Infections/immunology ; Tumor Virus Infections/pathology
    Raport
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Erratum: mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype.
    Autorzy:
    Herranz N
    Gallage S
    Mellone M
    Wuestefeld T
    Klotz S
    Hanley CJ
    Raguz S
    Acosta JC
    Innes AJ
    Banito A
    Georgilis A
    Montoya A
    Wolter K
    Dharmalingam G
    Faull P
    Carroll T
    Martínez-Barbera JP
    Cutillas P
    Reisinger F
    Heikenwalder M
    Miller RA
    Withers D
    Zender L
    Thomas GJ
    Gil J
    Pokaż więcej
    Źródło:
    Nature cell biology [Nat Cell Biol] 2015 Oct; Vol. 17 (10), pp. 1370.
    Typ publikacji:
    Published Erratum
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype.
    Autorzy:
    Herranz N; Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
    Gallage S; Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.; Metabolic Signalling Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
    Mellone M; Cancer Sciences Unit, Cancer Research UK Centre, Somers Building, University of Southampton, Southampton SO16 6YD, UK.
    Wuestefeld T; Division of Molecular Oncology of Solid Tumors, Department of Internal Medicine I, Eberhard Karls University Tübingen, 72076 Tübingen, Germany.
    Klotz S; Division of Molecular Oncology of Solid Tumors, Department of Internal Medicine I, Eberhard Karls University Tübingen, 72076 Tübingen, Germany.
    Hanley CJ; Cancer Sciences Unit, Cancer Research UK Centre, Somers Building, University of Southampton, Southampton SO16 6YD, UK.
    Raguz S; Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
    Acosta JC; Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
    Innes AJ; Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
    Banito A; Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
    Georgilis A; Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
    Montoya A; Proteomics Facility, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
    Wolter K; Division of Molecular Oncology of Solid Tumors, Department of Internal Medicine I, Eberhard Karls University Tübingen, 72076 Tübingen, Germany.
    Dharmalingam G; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
    Faull P; Proteomics Facility, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
    Carroll T; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
    Martínez-Barbera JP; Developmental Biology and Cancer Programme, Birth Defects Research Centre, UCL Institute of Child Health, London WC1N 1EH, UK.
    Cutillas P; Proteomics Facility, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
    Reisinger F; Institute for Virology, Technische Universität München/Helmholtz Zentrum München, 81675 Munich, Germany.
    Heikenwalder M; Institute for Virology, Technische Universität München/Helmholtz Zentrum München, 81675 Munich, Germany.; Division of Chronic Inflammation and Cancer, German Cancer Research (DKFZ), 69121 Heidelberg, Germany.
    Miller RA; Department of Pathology and Geriatrics Center, University of Michigan, Ann Arbor, Michigan 48109-2200, USA.
    Withers D; Metabolic Signalling Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
    Zender L; Division of Molecular Oncology of Solid Tumors, Department of Internal Medicine I, Eberhard Karls University Tübingen, 72076 Tübingen, Germany.
    Thomas GJ; Cancer Sciences Unit, Cancer Research UK Centre, Somers Building, University of Southampton, Southampton SO16 6YD, UK.
    Gil J; Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
    Pokaż więcej
    Źródło:
    Nature cell biology [Nat Cell Biol] 2015 Sep; Vol. 17 (9), pp. 1205-17. Date of Electronic Publication: 2015 Aug 17.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Protein Biosynthesis*
    Intracellular Signaling Peptides and Proteins/*metabolism
    Phosphoproteins/*metabolism
    Protein Serine-Threonine Kinases/*metabolism
    Proteome/*metabolism
    TOR Serine-Threonine Kinases/*physiology
    Animals ; Cell Line, Tumor ; Cellular Senescence ; Female ; HEK293 Cells ; Humans ; Intracellular Signaling Peptides and Proteins/genetics ; Mice, Nude ; Neoplasm Transplantation ; Protein Serine-Threonine Kinases/genetics
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT.
    Autorzy:
    Innes AJ; Centre for Haematology, Faculty of Medicine, Imperial College London, London, UK.
    Beattie R
    Sergeant R
    Damaj G
    Foroni L
    Marin D
    Kanfer E
    Mielke S
    Milojkovic D
    MacDonald D
    Pavlu J
    Rahemtulla A
    Roberts I
    Slade D
    Bray E
    Goldman J
    Apperley J
    Szydlo R
    Dazzi F
    Rezvani K
    Pokaż więcej
    Źródło:
    Bone marrow transplantation [Bone Marrow Transplant] 2013 Oct; Vol. 48 (10), pp. 1324-8. Date of Electronic Publication: 2013 May 20.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antibodies, Monoclonal, Humanized/*therapeutic use
    HLA Antigens/*immunology
    Leukemia/*therapy
    Stem Cell Transplantation/*methods
    T-Lymphocytes/*transplantation
    Adolescent ; Adult ; Alemtuzumab ; Female ; Histocompatibility/immunology ; Humans ; Leukemia/drug therapy ; Leukemia/immunology ; Leukemia/surgery ; Male ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/immunology ; Neoplasm Recurrence, Local/therapy ; Retrospective Studies ; T-Lymphocytes/immunology ; Transplantation, Homologous ; Treatment Outcome ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Dark chocolate inhibits platelet aggregation in healthy volunteers.
    Autorzy:
    Innes AJ; University Department of Medicine, Ninewells Hospital and Medical School, Dundee.
    Kennedy G
    McLaren M
    Bancroft AJ
    Belch JJ
    Pokaż więcej
    Źródło:
    Platelets [Platelets] 2003 Aug; Vol. 14 (5), pp. 325-7.
    Typ publikacji:
    Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Cacao*
    Platelet Aggregation Inhibitors*
    Blood Platelets ; Cardiotonic Agents ; Collagen ; Humans ; Platelet Activation ; Platelet Function Tests
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-9 z 9

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies